3D Systems: Healthcare And Metal Pivot Drives Re-Rating

Moretus Research initiated a Strong Buy rating on 3D Systems (NYSE:DDD) with a $4 price target, driven by the company's strategic pivot into healthcare and metal additive manufacturing. This, combined with a cost structure reset and the Geomagic divestiture, is expected to stabilize margins and enhance operational flexibility, positioning DDD for a significant recovery post-FY25. While near-term topline headwinds persist, the valuation anticipates an above-consensus FY26 recovery, with healthcare and dental expansion, particularly NextDent 300, highlighted as underappreciated catalysts for patient investors.

Analysis

Moretus Research has initiated coverage on 3D Systems Corporation (DDD) with a Strong Buy rating and a $4 price target, signaling a bullish outlook based on a strategic transformation. The core of this thesis rests on the company's pivot towards higher-margin healthcare and metal additive manufacturing sectors, a move supported by operational restructuring. Key actions, including a cost structure reset and the divestiture of the Geomagic software business, are expected to stabilize margins and improve liquidity, providing the flexibility needed for a turnaround. While the analysis acknowledges the existence of near-term topline headwinds, it frames the current valuation as a conservative fiscal year 2025 estimate, with a significant, above-consensus recovery projected for fiscal year 2026. The expansion in healthcare and dental, particularly through the NextDent 300 platform, is highlighted as an underappreciated catalyst that could drive a market re-rating. This positions the stock as a favorable risk/reward opportunity for patient investors awaiting the ramp-up of these new platforms.

Key Decisions for Investors

• Investors with a long-term horizon could view the current period of topline headwinds as a strategic entry point, aligning with the analyst's post-FY25 recovery thesis.
• Monitor key performance indicators related to the healthcare and dental segments, specifically the adoption and revenue contribution of the NextDent 300 platform, as this is cited as a primary catalyst for future growth.
• Given the forecast for a recovery materializing in FY26, positions in DDD should be considered with patience, acknowledging that the company is undergoing a multi-year operational and strategic pivot.